Crohn's & Colitis UK are disappointed in these decisions and regret that this treatment will only be available to patients in Scotland and Wales through Independent Patient Treatment/Funding Request processes. 

We will continue working to ensure that the difference this - and other new treatments - may make to people with Crohn’s Disease and Ulcerative Colitis, is fully recognised and understood by those making the decisions.

We do this through submissions and consultation responses, based on the evidence provided by people with IBD and, where appropriate, nominating and supporting patient experts to present their experience directly to the decision-makers.

We would like to thank those who told us about their experience of iron deficiency anaemia (IDA) and current treatments.  This informed our submissions to both the Scottish Medicines Consortium (SMC) and The All Wales Medicines Strategy Group (AWMSG). 

See our submissions to the SMC & AWMSG.

More information about these decisions can be found at the Scottish Consortium and the All Wales Medicines Strategy Group.